Publications

Antimicrobial Activity of Ceftaroline and Comparator Agents Tested Against Bacterial Isolates from Patients with Bacteremia in United States Medical Centers (2012), Lead author: Sader HS, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Antimicrobial Activity of Ceftaroline Tested against Contemporary (2012) Bacteria Isolated from Community-Acquired Respiratory Tract Infections, Including Oxacillin-resistant S. aureus, Lead author: Sader HS, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Antimicrobial Activity of Ceftaroline Tested against Multidrug Resistant (MDR) Streptococcus pneumoniae in the USA (2009-2012), Lead author: Flamm R, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Serotype distribution of Streptococcus pneumoniae recovered principally from non-sterile sites in patients aged =18 years in the US (2009-2011), Lead author: Hollingsworth RC, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Streptococcus pneumoniae serotype 3 recovered predominantly from non-sterile sites in patients aged =18 years in the USA (2009-2011), Lead author: Hewlett D, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Post Beta-Lactamase Inhibitor Effect of Tazobactam when Associated with Ceftolozane and Tested against ESBL-Producing Strains, Lead author: Sader HS, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Relationship between Ceftolozane/Tazobactam Exposure and E. coli Resistance Amplification Prevention in a Hollow Fiber Infection Model, Lead author: VanScoy, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Identification of a Translational Relationship Between Tazobactam Exposure in Combination with Ceftolozane and Efficacy against ESBL-Producing Enterobacteriaceae, Lead author: Ambrose PG, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

PK/PD of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model, Lead author: Nicasio, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Characterization of KPC-producing Klebsiella pneumoniae Isolates with Decreased Cefepime MIC Values: Negative Correlation with Clonal Complex 258, Lead author: Castanheira M, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Epidemiological Evidence for Glycopeptide Resistance Involvement in Persistence of Agr-defective Mutants among Methicillin-resistant Staphylococcus aureus (MRSA), Lead author: Shopsin, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Report of Linezolid Activity from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program 2012 (Europe, Latin America, Asia Pacific, Canada), Lead author: Flamm R, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Oritavancin activity against S. aureus Causing Invasive Infections in USA and European Hospitals: A Five-year International Surveillance Program, Lead author: Mendes RE, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Activity of Oritavancin Tested against Uncommonly Isolated Gram-positive Pathogens Responsible for Documented Infections in Hospitals Worldwide, Lead author: Mendes RE, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Antimicrobial Activity of Ceftaroline Tested against 10,956 Organisms Causing Acute Bacterial Skin and Skin Structure Infections in United States Medical Centers (2012), Lead author: Sader HS, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Activity of Ceftazidime-avibactam Tested against Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Gram-negative Pathogens from the Europe-Mediterranean Region, China and USA, Lead author: Flamm R, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Antimicrobial Activity of Ceftazidime-avibactam Tested against Contemporary (2012) Gram-negative Organisms Collected from United States Medical Centers, Lead author: Sader HS, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Ceftazidime-avibactam and Comparator Agents Tested against Urinary Tract Isolates from a Global Surveillance Program (2011), Lead author: Flamm R, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Activity of Ceftazidime-avibactam and Comparator Agents Tested against Isolates from Europe-Mediterranean Region Surveillance (2011), Lead author: Flamm R, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Antimicrobial Activity of Ceftolozane/tazobactam Tested against Gram-negative Bacterial Isolates from Hospitalized Patients with Pneumonia in United States and European Hospitals (2012), Lead author: Sader HS, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Ceftaroline-avibactam Tested against Contemporary (2012) Isolates Collected from United States Hospitals with Well Characterized &#223-lactamases, Lead author: Castanheira M, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Activity of Ceftazidime-avibactam Tested against Contemporary Pathogens from Hospitalized Pneumonia Patients in the USA (2012), Lead author: Flamm R, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Activity of the Fluoroquinolone JNJ-Q2 Tested against Contemporary (2012) Pathogens Isolated from the Global SENTRY Surveillance Platform, Lead author: Flamm R, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

S. pneumoniae Serotype Distribution and Antimicrobial Susceptibility Prior to and Post USA Introduction of 13-valent Pneumococcal Conjugate Vaccine, Lead author: Mendes RE, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Ceftriaxone Non-susceptibility in Emerging (35B) and Persisting (19A, 19F) S. pneumoniae Serotypes in the USA (2011 – 2012): Only Ceftaroline Retains Activity among &#223-lactams, Lead author: Mendes RE, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Genotypic Characterization of Methicillin-resistant Staphylococcus aureus Strains Recovered from Pneumonia Clinical Trials for Ceftobiprole, Lead author: Mendes RE, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Interim use of Vancomycin Susceptibility Testing Results to Predict Activity of Oritavancin, a New Long Acting Lipoglycopeptide, Lead author: Jones RN, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Re-evaluating the Contemporary (2007-2011) Spectrums of Tetracyclines (Minocycline, Doxycycline, and Tetracycline) Tested against Enterobacteriaceae and Acinetobacter spp., Lead author: Jones RN, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

In Vitro Activity Of The Novel Pleuromutilin BC-3781 Tested against Bacterial Pathogens Causing Sexually Transmitted Diseases, Lead author: Paukner, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Activity Activity of Cadazolid against Gram-positive Clinical Isolates, Including Linezolid-resistant Subsets with Defined Resistance Mechanisms, Lead author: Mendes RE, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Activity of ß-lactam Agents Tested in Combination with Novel &#223-lactamase Inhibitor Compounds against Enterobacteriaceae Producing Extended-spectrum ß-lactamases, Lead author: Mendes RE, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

ß-lactam Activity Tested in Combination with β-lactamase Inhibitor Candidates against Enterobacteriaceae Producing Class A, B and D Carbapenemases, Lead author: Mendes RE, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

In Vitro Activity of AZD0914: A New Benzisoxazole DNA Gyrase Inhibitor against Neisseria gonorrhoeae, Lead author: Huband, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Activity of the First-in-class Lpxc Inhibitor ACHN-975 and Comparators Tested against Gram-negative Organisms Including Isolates with Characterized Resistance Mechanisms, Lead author: Castanheira M, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Comparison of EUCAST and CLSI Broth Microdilution Methods for the Susceptibility Testing of 10 Systemically Active Antifungal Agents against Candida spp., Lead author: Castanheira M, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Intra- and Interlaboratory Study of Antifungal Susceptibility Testing of Isavuconazole against Aspergillus Strains, Lead author: Ghannoum, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Detection of fks Gene Hot Spot Mutations in Candida glabrata by CLSI Broth Microdilution Testing of Anidulafungin, Caspofungin and Micafungin using Epidemiological Cutoff Values, Lead author: Castanheira M, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Use of Micafungin as a Surrogate Marker to Predict Susceptibility and Resistance to Caspofungin among 3,747 Clinical Isolates of Candida using CLSI Methods and Interpretive Criteria, Lead author: Castanheira M, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Activity of Isavuconazole and Comparator Antifungals Tested against Contemporary (2012) Fungal Clinical Isolates Collected Worldwide, Lead author: Castanheira M, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

MALDI-TOF MS Identification of Clinically Significant Yeasts and Moulds in a Global Antifungal Surveillance Program, Lead author: Woosley LN, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Antimicrobial Activity of Ceftaroline and Comparator Agents against 6,502 S. pneumoniae Isolates from United States Medical Centers over 5 Years (2008-2012), Lead author: Sader HS, presented at American Thoracic Society (ATS), May 17 – 22, 2013, Philadelphia, PA

Prevelance of &#223-lactamase-encoding Genes in Escherichia coli Strains Collected in the USA: Report of the SENTRY Antimicrobial Susceptibility Program, Lead author: Castanheira M, presented at 113th annual American Society for Microbiology General Meeting (ASM), May 18 – 21, 2013, Denver, CO

Comprehensive Update of Dalbavancin Activity when Tested against Uncommonly Isolated Streptococci, Corynebacterium spp., Listeria monocytogenes and Micrococcus spp., Lead author: Jones RN, presented at 113th annual American Society for Microbiology General Meeting (ASM), May 18 – 21, 2013, Denver, CO

Activity of ceftobiprole tested against Gram-negative clinical isolates from European medical centres, Lead author: Flamm R, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Activity of ceftobiprole tested against clinical isolates of staphylococci and streptococci from European surveillance (2008-2010), Lead author: Flamm R, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus including strains with reduced susceptibility to daptomycin, linezolid, and vancomycin, Lead author: Flamm R, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Antimicrobial activity of ceftolozane/tazobactam and comparator agents tested against Pseudomonas aeruginosa isolates from 14 European countries and Israel, Lead author: Sader HS, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Oritavancin activity tested against Staphylococcus aureus and beta-haemolytic streptococci causing skin and soft tissue infections in the European Union and other countries (2010-2012), Lead author: Mendes RE, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Assessment of oritavancin activity tested against contemporary clinical isolates responsible for documented bacteremia in the European Union and other countries (2010-2012), Lead author: Mendes RE, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Dalbavancin activity in the USA: reported from the SENTRY Programme (2012), Lead author: Jones RN, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany